A New Pancreatic Cancer Pill Lists at $39,800 a Month, and What Patients Actually Owe Varies Widely
Revolution Medicines priced its new pancreatic cancer drug, Rasonque, at $39,800 per month, or $477,600 annually. The company expects discounts and rebates to reduce the effective price by 20-30%. Medicare patients face an out-of-pocket cap, while commercially insured patients may encounter high initial costs due to deductible resets. The drug showed significant survival benefits in clinical trials, according to the company and health experts.
How this was made
The 30-second read
Why it matters
The announcement introduces a new high-cost oncology option, affecting pricing dynamics and payer strategies.
Market read
The approval and pricing could drive volatility in RVMD and influence broader oncology sector sentiment.
What to watch
Potential for patient assistance programs and government rebates could mitigate out-of-pocket costs, supporting adoption.
Background
First public disclosure of the FDA approval and list price for Revolution Medicines' new pancreatic cancer therapy.
Ticker impact
Revolution Medicines disclosed FDA approval of its pancreatic cancer pill Rasonque and set a $39,800 list price in a securities filing.
Potential short-term volatility with a slight downside bias pending market reaction to pricing details.
Approval is positive, but the $39.8k monthly price is unusually high, likely leading to mixed investor sentiment.
Market effects
Highlights pricing pressure in oncology and may influence valuations of other high-cost cancer therapeutics.
U.S. market, especially Medicare and commercial insurers, will assess coverage and rebate strategies.
Sets a precedent for pricing of breakthrough cancer drugs worldwide.
Counterpoint
Investors may view the approval as a catalyst for long-term growth if reimbursement improves, outweighing short-term price concerns.
Key entities
- CompanyRevolution Medicines
US-listed biotech (NASDAQ: RVMD) that received FDA approval for Rasonque.
- DrugRasonque (daraxonrasib)
New pancreatic cancer pill with a $39,800 monthly list price.
